Test Price
2,800 AED✅ Home Collection Available
HNRNPU Gene RNA Processing‑Related Disorders Genetic Test in UAE | 2800 AED | DHA‑Licensed NGS with Transcriptome Analysis
Executive Summary & Core Metrics
- Diagnostic Accuracy 99.9% – Next‑Generation Sequencing (NGS) with full RNA transcriptome analysis under ISO 9001:2015 (Cert. INT/EGQ/2509DA/3139).
- VIP Mobile Phlebotomy & Cold‑Chain Logistics – Temperature‑controlled home collection available daily from 8 AM to 11 PM across Dubai, Abu Dhabi, and all UAE emirates.
- Post‑Test Clinical Guidance – Complimentary tele‑consultation with a Consultant Medical Geneticist for result interpretation and family risk assessment.
- Insurance Verification – Direct billing support via WhatsApp +971 54 548 8731 for pre‑authorised plans.
Test Overview & Methodology
The HNRNPU Gene RNA Processing‑Related Disorders Genetic Test is a high‑resolution molecular assay that sequences the entire HNRNPU gene and its RNA transcripts. It detects pathogenic variants associated with intellectual disability, epilepsy, and syndromic dysmorphology, providing a definitive diagnosis in 3–4 weeks. By coupling genomic DNA sequencing with transcriptome profiling, this test captures splicing aberrations and non‑coding variants that standard DNA‑only methods routinely miss.
| Feature | Our Test – Amplicon NGS + Transcriptome | Alternative – Sanger Sequencing Only |
|---|---|---|
| Methodology | Targeted NGS with parallel RNA transcriptome analysis | Capillary (Sanger) sequencing – DNA only |
| Detection Sensitivity | 99.9% for SNVs, indels, and splicing variants | ~95% – misses deep intronic and transcript‑level aberrations |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
| Regulatory Clearance | DHA‑Licensed, ISO 9001:2015, PDPL Compliant | Often limited to research‑use only |
Physician Insight & Safety Protocols
“For children presenting with developmental regression, refractory seizures, or multiple congenital anomalies, this combined NGS and transcriptome assay provides a comprehensive molecular diagnosis that single‑gene or DNA‑only approaches cannot achieve. A positive result clarifies the genetic basis and recurrence risk; a negative result does not exclude all hereditary aetiologies and must be interpreted alongside the full clinical phenotype by a qualified medical geneticist. Do not discontinue any prescribed medication without consulting your physician.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Safety Exclusion Criteria
- Paediatric Consent: Testing in minors requires documented clinical indication, parental consent, and a formal genetic counselling session in accordance with UAE federal regulations.
- Patients with active febrile illness (>38°C) or acute infection should postpone sample collection until symptoms resolve.
- Emergency: In case of sudden uncontrolled seizures, loss of consciousness, or severe respiratory distress, seek immediate emergency care before proceeding with genetic testing.
Medication Advisory
Do not discontinue any prescribed anticonvulsant, neurodevelopmental, or behavioural medication without consulting your treating physician. This genetic test does not alter existing treatment plans without medical oversight.
Patient FAQ & Clinical Guidance
1. What does the HNRNPU NGS with transcriptome test actually detect?
It precisely identifies single‑nucleotide variants, small insertions/deletions, and splicing abnormalities in the HNRNPU gene by sequencing both genomic DNA and complementary RNA. This dual‑modality approach captures mutations that standard DNA‑only methods miss, raising the diagnostic yield for intellectual disability and epileptic encephalopathy syndromes to 99.9%.
2. How long does it take to receive results in the UAE?
The official turnaround time is 3 to 4 weeks from sample reception at our ISO‑certified UAE laboratory. A digital report is delivered directly to your physician, and an optional tele‑consultation with our Consultant Medical Geneticist can be arranged for result interpretation.
3. Is this genetic test covered by health insurance in Dubai and Abu Dhabi?
Many UAE health plans cover this test when pre‑authorised by a specialist (paediatrician, geneticist) for a clinically indicated reason. Our team verifies your policy and handles direct billing via WhatsApp: +971 54 548 8731.
4. What sample is required, and how is it collected?
A standard peripheral blood sample (3–5 mL in EDTA) is required. Collection is performed via VIP Mobile Phlebotomy at your home or workplace using temperature‑controlled cold‑chain logistics, available daily from 8 AM to 11 PM. No hospital visit is necessary.
5. Will the test results affect my child’s current treatment plan?
The results provide diagnostic clarity but do not automatically change existing medications. Any treatment adjustment must be made by the treating physician in consultation with a medical geneticist. Genetic counselling is recommended to discuss recurrence risks and family implications.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Data Protection: All patient genetic and clinical data processed in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Governance: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for secure electronic health records and tele‑consultation.
- Clinical Safety: Patient consent and medical liability governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- DHA Licensing: Facility licensed by the Dubai Health Authority under license number 1143.
Clinical & Logistical Metadata
| Test Name | HNRNPU Gene RNA Processing‑Related Disorders NGS with Transcriptome Analysis |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM – 11 PM) |
| Methodology Used | Targeted Amplicon Next‑Generation Sequencing (NGS) with Parallel RNA Transcriptome Analysis |
| ICD-10-CM Code | Q87.8 (Other specified congenital malformation syndromes affecting multiple systems), F70 (Mild intellectual disability) |
| LOINC Code | 95424-2 (Single gene mutation analysis by NGS in blood) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians